Dr. Song is a Scientist III with ToxStrategies, based in Southern California. Dr. Song has postdoctoral and research experience focusing on applications of physiologically based pharmacokinetic (PBPK) modeling techniques to assess early-life sensitivity to drugs and compounds, and combining modeling with in vitro–to–in vivo extrapolation (IVIVE). As a postdoctoral research fellow at the University of Southern California, she evaluated potential effects of glucagon on insulin kinetics in mice using population modeling analysis. She also quantified pharmacokinetic bias in epidemiological associations between environmental chemicals and human health effects using PBPK modeling, and pursued multiple research topics as a postdoctoral fellow at the Hamner Institutes for Health Sciences. She earned her Ph.D. in Pharmaceutical Sciences from the University of North Carolina, where her research focused on evaluating immune mechanisms affecting pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal anticancer agents. Dr. Song’s areas of expertise also include preclinical and clinical pharmacology, and PK/PD analyses of preclinical and clinical data.